By CJ Evans, Co-Founder, Alternative Fuels & Chemicals Coalition, Project Manager, Federal Funding Services Special to The Digest Editor’s Note: CJ Evans and his teams of subject matter experts have helped more than 250 companies of all sizes prepare applications for federal grants and loan guarantees over the past 20 years. He has seen far […]
Ten years ago, Visolis entered the federal innovation pipeline through Cyclotron Road—the DOE-backed fellowship that helped define the climate-tech generation. Founder Deepak Dugar was part of a wave of scientists trying to turn low-carbon chemistry into real industry. Today, Visolis is winning scale-up funding from the Department of Defense. Same company. Same core science. Different […]
Dyadic is pivoting from R&D to revenue generation with recombinant protein product launches slated for 2025–2027. Highlights include successful Phase 1 results for their DYAI-100 COVID-19 vaccine candidate and significant funding wins—a $4.5 million CEPI grant and $3 million from the Gates Foundation—to accelerate affordable vaccine and mAb production for global health. The company is […]
There’s a quiet bond among people who choose this work, the bioeconomy. You don’t end up here because it’s easy. If easy were the goal, there are cleaner career paths, simpler markets, less friction. Heck, go get rich working on petroleum. Here, progress comes with resistance. Every gain seems to arrive with a counterforce — […]
dsm-firmenich is advancing its strategic portfolio transformation by separating its Animal Nutrition & Health business, with an exit expected in 2025. The company is focusing on high-growth segments in Nutrition, Health, and Beauty, showcasing innovations like plant-based tuna alternatives and microbiome-targeted gut health solutions. Financial highlights include a planned €1 billion share buyback, the completion […]
In Washington, Growth Energy was very unhappy after it was announced that a legislative fix for year-round E15 was dropped from the January government funding bill. It was further incensed that Congress would instead form a “rural energy council” to formulate another compromise bill with petroleum interests, and with expectations for a vote in February. […]
Corteva is on track to separate into two independent market leaders by late 2026, with the “New Corteva SpinCo” focusing on advanced genetics, gene editing, and biofuels. Commercially, the company raised its full-year 2025 operating EBITDA guidance to 3.80–3.90 billion, driven by strong seed volumes in North America and new crop protection product gains. The […]
Corbion has launched its “BRIGHT 2030” strategy, pivoting toward fermentation-based natural preservation and nutrition while initiating a strategic review of its PLA portfolio. The company highlights its leadership in algae-derived omega-3 oils, securing long-term aquaculture contracts and expanding into nutraceuticals. Commercial highlights include double-digit growth in biomedical polymers driven by the UZEDY® partnership with MedinCell. […]
The spreadsheet worked. The chemistry was sound. The model penciled. And yet the project stalled, downsized, or died somewhere between final investment decision and steel in the ground. If you’ve worked on a first-of-a-kind (FOAK) project in the bioeconomy, this story will feel familiar. The usual explanations follow: demand softness, policy uncertainty, buyer hesitation, macro […]
Codexis is positioning its ECO Synthesis® platform to capture the growing RNAi therapeutics market, recently demonstrating process reproducibility with partners like Bachem and Nitto Avecia. Technical highlights include a new proprietary machine learning tool for optimized enzymatic ligation and the ability to control stereochemistry in siRNA synthesis. Commercially, the company reported a cash runway extending […]
